Celltrion’s New Autoimmune Disease Treatment Zymfentra Hits U.S. Market

SEOUL, Mar. 18 (Korea Bizwire) — South Korean biopharmaceutical firm Celltrion Inc. said Monday its new autoimmune disease treatment, Zymfentra, has made a debut in the U.S. market. Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last year for use on patients who suffer ulcerative [...]

Celltrion’s New Autoimmune Disease Treatment Zymfentra to Hit U.S. Market in Feb.

SEOUL, Nov. 30 (Korea Bizwire) — Celltrion Healthcare Co. said Thursday its new autoimmune disease treatment, Zymfentra, will make its U.S. market debut on Feb. 29 next year. Zymfentra, a subcutaneous injection formulation of Celltrion’s infliximab Remsima, won approval from the U.S. Food and Drug Administration last month. The sales affiliate of South Korean pharmaceutical [...]